PremiumCompany AnnouncementsAdvaxis Clarifies CMO Bonus Terms Amid Asset Sale Advaxis Asset Sale Approved by Majority Shareholder Vote Advaxis Executes Strategic Unregistered Equity Sales PremiumCompany AnnouncementsAdvaxis Announces Definitive Agreement with Ayala Pharmaceuticals Immunome to acquire AL102 from Ayala for $20M in cash, $30M in stock Ayala Pharmaceuticals downgraded to Neutral from Buy at Ladenburg PremiumThe FlyAyala Pharmaceuticals, Biosight enter definitive merger agreement Ayala announces End-of-Phase 2 meeting with FDA on AL102 in desmoid tumors Biotech Alert: Searches spiking for these stocks today 
